Navigation Links
Factors influencing delay in breast cancer treatment differ for African-American and white women
Date:7/10/2013

CHAPEL HILL, N.C. Different factors influence delay between diagnosis and first course of treatment for breast cancer for African-American and White women.

The study used data from the Carolina Breast Cancer Study (CBCS) Phase III, a program of UNC Lineberger Comprehensive Cancer Center. Scientists found that among White women, household size and losing a job due to one's diagnosis were reasons for delay in treatment, while among African-American women, the type of treatment received influenced delay. Both African-American and White women experienced delay if they underwent immediate breast reconstruction following mastectomy. African-American women were more likely than White women to experience delay associated with this procedure (92.5 percent versus 60.6 percent).

The study was published in the July 3, 2013 issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

The researchers categorized women into two groups: those who received treatment within 30 days of diagnosis, and those whose treatment was delayed by more than 30 days.

"Our goal was to identify the factors that contribute to treatment delay and to assess whether disparities in delay exist between African-American and White women," said Sasha McGee, PhD, an epidemiology graduate student at the University of North Carolina Gillings School of Global Public Health at the time of this study.

The study found that African-American women between the ages of 20 and 49 were more than three times as likely as White women in this age range to experience treatment delay.

"The study results suggest that specific populations of women need to be targeted when characterizing and addressing determinants of treatment delay, and that younger African-American women may benefit from interventions to reduce disparities in treatment delay," said McGee.

The study population consisted of 601 women with breast cancer between the ages of 20 and 74, who were enrolled in the CBCS between 2008 and 2010. The CBCS is an ongoing population-based study that recruits women from 44 counties in in North Carolina. "We used information from interviews and questionnaires to collect socioeconomic data for each woman," McGee added. "Larger studies often use area-level information for groups of people [e.g. based on census data] and apply these data to individuals in the study, which may not always be accurate." Clinical and treatment information were obtained by reviewing the medical records for each study participant.

"One of the goals of the CBCS Phase III is to assess five- and ten-year survival for study participants once recruitment ends in 2014. Follow-up interviews for study participants will continue for up to five years after diagnosis, therefore not only will we be able to evaluate the impact of a treatment delay of more than 30 days on survival, but also the impact of barriers to treatment and healthcare access," said McGee.


'/>"/>

Contact: Dianne Shaw
dgs@med.unc.edu
919-966-7834
University of North Carolina Health Care
Source:Eurekalert

Related medicine news :

1. Program and registration open for International Annual Meeting of Human Factors/Ergonomics Professionals
2. Patient factors play key role in emergency department imaging
3. Risk factors affect the incidence of childhood pneumonia in modern urban apartment?
4. Risk Factors of Skin Cancer & Reducing That Risk
5. icandrive.ca Provides Tips to Understand the Top Factors That Affect Car Insurance Premiums
6. RKNet Studios Announced Cognitions Bridge Games for Senior Adults; to Fight Loneliness and Cognitive Decline, the Known Risk Factors in Early Death
7. Suicide risk factors mapped
8. hyperCision Inc. Announces Its Learning Migration Rapid-Deployment Solution for Helping Customers Migrate from SAP® Enterprise Learning to SuccessFactors Learning
9. Twenty-Eight Percent of Adult Americans Have Risk Factors for Pre-Diabetes But Five Out of Six Don’t Know It
10. A Number of Factors Contribute to Rise in Drug Addiction for Middle-Aged Women, According to KLEAN Treatment Center
11. Dr. Kanani, Woodland Hills Dentist, Offers Tips on Managing Risk Factors for Tooth Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT campaign, Robert Herjavec ... it’s not if you will be attacked, but when.” However, he and many others ... health care. , Improvements in auditing and monitoring have taken security in health care ...
(Date:2/24/2017)... ... 2017 , ... The narrative in “ Signal 8: An Australian Paramedic’s Story ... his paramedic experiences. Schanssema describes the tragedies he saw, as well as his struggles ... , Schanssema, initially unsure of the career path he wanted to take, found fulfillment ...
(Date:2/24/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... Yisrayl makes an astounding statement when he says that the entire Bible was ... details the current times so plainly that anyone should be able to see the ...
(Date:2/24/2017)... Farifax, VA (PRWEB) , ... February 24, 2017 , ... ... winners for excellence in radiology marketing programs at the annual Building Better ... the Worthington Renaissance Fort Worth Hotel in Fort Worth, Texas. Nine awards are given ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, the ... Military Wedding Giveaway, with the winning couple announced on Feb. 14, 2017, on ... donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A Touch ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... BRISBANE, Australia , Feb. 23, 2017  Directors from Pharma ... the two companies have joined forces, resulting in the founding of ... . Pharma To Market are pleased to announce their ... an office in Singapore . The company are ... Consulting as Co-Director of the Singapore based ...
(Date:2/24/2017)... -- Xynomic Pharmaceuticals, Inc., an oncology drug research and ... exclusive worldwide rights to develop, manufacture and commercialize ... hematological and solid tumors. To date ... clinical trials of Abexinostat in US, EU and ... completed, demonstrating that Abexinostat is clinically active in ...
(Date:2/23/2017)... 2017 LG Innotek hat heute die weltweit ... beträgt das 1,5-fache des 45-mW-Moduls der Konkurrenz. ... 200 und 280 nm und eignet sich damit für Sterilisationsaufgaben. ... DNA zerstört. Das Produkt von LG Innotek erzeugt UV-Strahlung ... ...
Breaking Medicine Technology: